The Academy of Managed Care Pharmacy (AMCP) thanks the Institute of Clinical and Economic Review (ICER) for the opportunity to provide comments in response to the national call for suggestions on how to improve its value assessment framework released on July 14, 2016.
The Academy of Managed Care Pharmacy (AMCP) urges you to sign Assembly Bill 1114, legislation that would make certain pharmacist provided services a covered benefit under the Medi-Cal program. As health care delivery in the United States continues to evolve and the focus on an interdisciplinary team approach to patient care increases, it is critical to recognize the value of pharmacists as health care providers.
Press Release: Two nationally recognized managed care pharmacy experts have been appointed to influential advisory panels of the Patient-Centered Outcomes Research Institute (PCORI) based on joint nominations by the Academy of Managed Care Pharmacy (AMCP) and AMCP Foundation.
AMCP CEO Blog: Last week I saw a headline that jumped off the page: “America’s other drug problem: Giving the elderly too many prescriptions” (Washington Post, Aug. 15).
The Academy of Managed Care Pharmacy (AMCP) respectfully requests that you support Assembly Bill 1114 that would make certain pharmacist provided services a covered benefit under the MediCal program. As health care delivery in the United States continues to evolve and the focus increases on an interdisciplinary team approach to patient care, it is critical to recognize the value of pharmacists as health care providers.
The undersigned pharmacist organizations thank the Food and Drug Administration (FDA) for the opportunity to provide comments on the reauthorization of the Prescription Drug User Fee Act (PDUFA) for fiscal years (FY) 2018 through 2022 as published in the Federal Register on July 19, 2016. Collectively, our organizations represent over 100,000 pharmacists across the full spectrum of health care practice settings.
The Academy of Managed Care Pharmacy (AMCP) opposes House Bill 976. This bill would amend Chapter 112 Section 12EE (a) by replacing the words “biosimilar and interchangeable” in the definition of “interchangeable biologic product” with the words “therapeutically equivalent to”. This new proposed definition is inconsistent with existing Massachusetts law, which follows the language in the Biologics and Price Competition and Innovation Act (BPCIA).
The Academy of Managed Care Pharmacy (AMCP) supports the passage of House Bill 2041. This legislation would recognize pharmacists as health care providers and authorize them to perform certain patient services including drug therapy management and administering drugs and biological products to a patient pursuant to a physician’s orders. As health care delivery in the United States continues to evolve and the focus increases on an interdisciplinary team approach to patient care, it critical to achieve better quality patient care that pharmacists are recognized as health care providers.
Press Release: Variations in how biosimilar products are named may affect the willingness of some pharmacists to substitute an interchangeable biologic for its branded reference product, according to a survey study published in this month’s Journal of Managed Care & Specialty Pharmacy (JMCP).